Wedbush Reaffirms Outperform Rating for Aerovate Therapeutics (NASDAQ:AVTE)
Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a report released on Tuesday, Benzinga reports. They currently have a $41.00 target price on the stock. Wedbush’s target price points to a potential upside of 95.15% from the stock’s current price. Wedbush also issued estimates […]
More Stories
Fauci Deputy Who Declined COVID-19 Vaccine Feared Retaliation: Emails
By Zachary Stieber A top government doctor who declined to receive a COVID-19 vaccine in 2021 was worried he would...
20+ SEO Checklist For Blog Posts: Read Before Publishing
You wrote a fantastic blog. What’s next? Publishing blogs without optimizing them for SEO is like starting a shop without...
US Military Blockade on Iranian Ports Goes Into Effect, Maritime Group Says
By Jack Phillips A scheduled U.S. naval blockade of the Strait of Hormuz and nearby waters started at 10 a.m....
Who is Jonathan Joly? Age, Marriage, and Net Worth in 2026
If you like to scroll on social media, the chances of you witnessing Jonathan Joly are high. Are you also...
Rory McIlroy Wins Back-to-Back Masters Titles to Join Jack Nicklaus, Nick Faldo, and Tiger Woods
By The Associated Press AUGUSTA, Ga.—Rory McIlroy joined more elite company Sunday at the Masters when he pulled away with...
At Least 30 Dead in Stampede at Haiti’s Historic Laferriere Citadel
By Reuters At least 30 people were killed on Saturday in a stampede in the northern countryside of Haiti, authorities...